Los Angeles Capital Management LLC Has $21.69 Million Position in Inspire Medical Systems, Inc. (NYSE:INSP)

Los Angeles Capital Management LLC increased its position in shares of Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 50.4% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 136,174 shares of the company's stock after buying an additional 45,632 shares during the period. Los Angeles Capital Management LLC owned 0.46% of Inspire Medical Systems worth $21,690,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in INSP. Vanguard Group Inc. increased its holdings in shares of Inspire Medical Systems by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 3,270,357 shares of the company's stock valued at $606,259,000 after purchasing an additional 38,219 shares during the last quarter. Dragoneer Investment Group LLC acquired a new position in shares of Inspire Medical Systems in the fourth quarter valued at $161,486,000. Invesco Ltd. increased its holdings in shares of Inspire Medical Systems by 14.3% in the fourth quarter. Invesco Ltd. now owns 793,080 shares of the company's stock valued at $147,021,000 after purchasing an additional 99,030 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Inspire Medical Systems by 12.9% in the fourth quarter. Janus Henderson Group PLC now owns 567,312 shares of the company's stock valued at $105,173,000 after purchasing an additional 64,703 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Inspire Medical Systems by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 486,341 shares of the company's stock valued at $90,188,000 after purchasing an additional 2,687 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 360 shares of the firm's stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $160.00, for a total transaction of $57,600.00. Following the completion of the sale, the director owned 24,046 shares of the company's stock, valued at $3,847,360. This trade represents a 1.48% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. 4.10% of the stock is currently owned by company insiders.

Inspire Medical Systems Stock Down 2.5%

Shares of INSP stock traded down $3.34 on Thursday, reaching $128.21. The company had a trading volume of 164,256 shares, compared to its average volume of 542,733. The stock has a market capitalization of $3.78 billion, a PE ratio of 59.08, a price-to-earnings-growth ratio of 1.98 and a beta of 1.25. Inspire Medical Systems, Inc. has a one year low of $123.00 and a one year high of $225.00. The business's 50-day moving average is $134.53 and its 200 day moving average is $158.34.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 7.92% and a return on equity of 10.00%. The business had revenue of $201.32 million during the quarter, compared to analyst estimates of $194.89 million. During the same quarter last year, the business earned ($0.34) EPS. The firm's quarterly revenue was up 22.7% on a year-over-year basis. On average, sell-side analysts forecast that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

INSP has been the topic of several research reports. Wells Fargo & Company decreased their price objective on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. lowered their price target on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 6th. Wall Street Zen upgraded shares of Inspire Medical Systems from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. Morgan Stanley dropped their price objective on shares of Inspire Medical Systems from $200.00 to $182.00 and set an "overweight" rating for the company in a research note on Tuesday, July 15th. Finally, Royal Bank Of Canada dropped their price objective on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a research note on Tuesday, April 15th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $208.55.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.